Haemonetics Corporation (NYSE:HAE) Receives $77.11 Average Price Target from Analysts

Posted by on Jun 4th, 2026

Shares of Haemonetics Corporation (NYSE:HAE – Get Free Report) have been given an average rating of “Moderate Buy” by the eleven research firms that are currently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, six have issued a buy rating and one has issued a strong buy rating on the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $77.1111.

A number of equities analysts have commented on HAE shares. Mizuho reduced their target price on Haemonetics from $80.00 to $70.00 and set an “outperform” rating for the company in a report on Monday, April 13th. Bank of America raised Haemonetics from a “neutral” rating to a “buy” rating and increased their target price for the company from $72.00 to $80.00 in a report on Friday, May 22nd. Weiss Ratings cut Haemonetics from a “hold (c-)” rating to a “sell (d+)” rating in a report on Thursday, May 21st. Citigroup increased their target price on Haemonetics from $64.00 to $70.00 and gave the company a “neutral” rating in a report on Thursday, May 28th. Finally, Wall Street Zen raised Haemonetics from a “hold” rating to a “buy” rating in a report on Saturday, May 23rd.

View Our Latest Research Report on HAE

Institutional Investors Weigh In On Haemonetics

Several hedge funds and other institutional investors have recently made changes to their positions in HAE. AQR Capital Management LLC increased its holdings in shares of Haemonetics by 372.8% in the third quarter. AQR Capital Management LLC now owns 2,128,878 shares of the medical instruments supplier’s stock valued at $102,814,000 after purchasing an additional 1,678,630 shares during the last quarter. Arrowstreet Capital Limited Partnership increased its holdings in shares of Haemonetics by 994.7% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 1,380,102 shares of the medical instruments supplier’s stock valued at $110,615,000 after purchasing an additional 1,254,035 shares during the last quarter. Millennium Management LLC increased its holdings in shares of Haemonetics by 4,296.3% in the third quarter. Millennium Management LLC now owns 773,179 shares of the medical instruments supplier’s stock valued at $37,685,000 after purchasing an additional 755,592 shares during the last quarter. North Peak Capital Management LLC increased its holdings in shares of Haemonetics by 204.4% in the fourth quarter. North Peak Capital Management LLC now owns 1,102,992 shares of the medical instruments supplier’s stock valued at $88,405,000 after purchasing an additional 740,626 shares during the last quarter. Finally, Invenomic Capital Management LP increased its holdings in shares of Haemonetics by 1,691.5% in the third quarter. Invenomic Capital Management LP now owns 498,317 shares of the medical instruments supplier’s stock valued at $24,288,000 after purchasing an additional 470,502 shares during the last quarter. Institutional investors and hedge funds own 99.67% of the company’s stock.

Haemonetics Price Performance

Shares of Haemonetics stock opened at $65.96 on Friday. The business has a 50 day simple moving average of $59.42 and a two-hundred day simple moving average of $67.27. Haemonetics has a 12 month low of $47.31 and a 12 month high of $87.32. The stock has a market capitalization of $3.00 billion, a P/E ratio of 32.65, a PEG ratio of 1.34 and a beta of 0.56. The company has a debt-to-equity ratio of 1.53, a current ratio of 2.95 and a quick ratio of 1.87.

Haemonetics (NYSE:HAE – Get Free Report) last announced its earnings results on Thursday, May 7th. The medical instruments supplier reported $1.29 EPS for the quarter, beating analysts’ consensus estimates of $1.28 by $0.01. Haemonetics had a return on equity of 27.30% and a net margin of 7.29%.The business had revenue of $346.35 million during the quarter, compared to analysts’ expectations of $336.83 million. During the same quarter in the prior year, the firm earned $1.24 earnings per share. The business’s revenue was up 4.8% compared to the same quarter last year. Haemonetics has set its FY 2027 guidance at 5.258-5.307 EPS. As a group, analysts predict that Haemonetics will post 5.23 EPS for the current fiscal year.

About Haemonetics

(Get Free Report)

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.

Read More

Analyst Recommendations for Haemonetics (NYSE:HAE)

Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.